◆ mixed
Impact
PhasePhase 2 (complete); preparing Phase 3
Time to marketAt least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
nebokitug Updated Jul 8
What to watch
The just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
Bull case
- PSC is a rare liver disease with ZERO FDA-approved disease-modifying therapies, nebokitug could be first-to-market if Phase 3 succeeds, addressing a high-unmet-need orphan population.
- Phase 2 SPRING trial showed dose-dependent improvements across fibrotic, inflammatory, and cholestatic biomarkers; results published in the American Journal of Gastroenterology, lending credibility.
- FDA and EMA both granted Orphan Drug designation; FDA also gave Fast Track status; FDA agreed to a single pivotal Phase 3 trial design without liver biopsy, lowering the regulatory bar.
Bear case
- Phase 3 PSC trial has NOT started, it remains contingent on financing. The merger gives $30M but Scipher shareholders get ~68% of the combined entity, massively diluting pre-merger CMMB holders.
- The stock closed at $2.13 on merger announcement day, down ~54% from the prior close of $4.64, suggesting the market interpreted the deal terms as unfavorable for Chemomab shareholders.
- Nebokitug is Chemomab's only asset, single-drug binary risk. A Phase 3 failure would leave the company with virtually nothing.